{
    "ticker": "CANF",
    "name": "Can-Fite BioPharma Ltd.",
    "description": "Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, focused on developing innovative therapies for cancer and inflammatory diseases. Founded in 2000, Can-Fite's proprietary drug candidates are based on its unique understanding of the role of the A3 adenosine receptor in the body. The company's lead product candidate, Namodenoson (CF101), is being developed for the treatment of liver cancer and is in late-stage clinical trials. Namodenoson has shown promise in improving survival rates and is designed to be administered orally, offering convenience for patients. Additionally, Can-Fite is exploring the use of its drug candidates for other indications, including psoriasis and rheumatoid arthritis. The company employs a strategic approach to drug development, collaborating with leading research institutions and biopharmaceutical companies to maximize the potential of its therapies. Can-Fite aims to bring its innovative treatments to market, addressing significant unmet medical needs and improving the quality of life for patients around the world. With a strong pipeline and a commitment to scientific excellence, Can-Fite is positioned to be a key player in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Petah Tikva, Israel",
    "founded": "2000",
    "website": "https://www.can-fite.com",
    "ceo": "Pnina Fishman",
    "social_media": {
        "twitter": "https://twitter.com/CanFite",
        "linkedin": "https://www.linkedin.com/company/can-fite-biopharma-ltd/"
    },
    "investor_relations": "https://www.can-fite.com/investor-relations/",
    "key_executives": [
        {
            "name": "Pnina Fishman",
            "position": "CEO"
        },
        {
            "name": "Dr. Roni Sofer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "Namodenoson (CF101)",
                "CF102",
                "CF105"
            ]
        }
    ],
    "seo": {
        "meta_title": "Can-Fite BioPharma Ltd. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and inflammatory diseases.",
        "keywords": [
            "Can-Fite",
            "Biotechnology",
            "Pharmaceuticals",
            "Cancer Treatments",
            "Namodenoson",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Can-Fite known for?",
            "answer": "Can-Fite is known for its development of innovative therapies for cancer and inflammatory diseases, particularly its lead product candidate Namodenoson."
        },
        {
            "question": "Who is the CEO of Can-Fite?",
            "answer": "Pnina Fishman is the CEO of Can-Fite BioPharma Ltd."
        },
        {
            "question": "Where is Can-Fite headquartered?",
            "answer": "Can-Fite is headquartered in Petah Tikva, Israel."
        },
        {
            "question": "What are Can-Fite's main products?",
            "answer": "Can-Fite's main products include Namodenoson (CF101), CF102, and CF105."
        },
        {
            "question": "When was Can-Fite founded?",
            "answer": "Can-Fite was founded in 2000."
        }
    ],
    "competitors": [
        "NTEC",
        "MDGL",
        "REPH"
    ],
    "related_stocks": [
        "APRI",
        "CBAY",
        "CRMD",
        "EIDX"
    ]
}